PURPOSE: The term "chemobrain" is sometimes used to denote deficits in neuropsychological functioning that may occur as a result of cancer treatment. As breast cancer survivors now commonly reach late life, it is not known whether previous exposure to chemotherapy may affect long-term risk for cognitive impairment. To help address this concern, this study tested whether successfully surviving chemotherapy earlier in life was associated with later differences in brain metabolic function as an older adult compared to controls. This question was examined using positron emission tomography measures of brain glucose metabolism in elderly women cancer survivors. METHODS: Breast cancer survivors (N = 10), currently free of recurrent cancer and without a diagnosis of a cognitive disorder, were compared to matched healthy controls (N = 10). All subjects were imaged at rest with [(18)F]fluorodeoxyglucose. Images were analyzed semi-quantitatively using the Alzheimer's Discrimination Tool and a volume of interest-based approach derived from co-registered magnetic resonance imaging. RESULTS: Relative [(18)F]fluorodeoxyglucose uptake (normalized to global) was significantly lower in the survivors compared with control subjects in bilateral orbital frontal regions, consistent with differences between the groups in cognition and executive function (i.e., Trail Making Test, Part B and mini-mental state examination) and despite no significant differences with respect to age, education, intelligence, or working memory. None of the survivors and only one control manifested a global positron emission tomography score consistent with an Alzheimer's disease metabolic pattern. CONCLUSION: Breast cancer survivors treated with chemotherapy may manifest long-term changes in brain glucose metabolism indicative of subtle frontal hypometabolism, a finding consistent with results from neuropsychological testing and other imaging modalities.
PURPOSE: The term "chemobrain" is sometimes used to denote deficits in neuropsychological functioning that may occur as a result of cancer treatment. As breast cancer survivors now commonly reach late life, it is not known whether previous exposure to chemotherapy may affect long-term risk for cognitive impairment. To help address this concern, this study tested whether successfully surviving chemotherapy earlier in life was associated with later differences in brain metabolic function as an older adult compared to controls. This question was examined using positron emission tomography measures of brain glucose metabolism in elderly womencancer survivors. METHODS:Breast cancer survivors (N = 10), currently free of recurrent cancer and without a diagnosis of a cognitive disorder, were compared to matched healthy controls (N = 10). All subjects were imaged at rest with [(18)F]fluorodeoxyglucose. Images were analyzed semi-quantitatively using the Alzheimer's Discrimination Tool and a volume of interest-based approach derived from co-registered magnetic resonance imaging. RESULTS: Relative [(18)F]fluorodeoxyglucose uptake (normalized to global) was significantly lower in the survivors compared with control subjects in bilateral orbital frontal regions, consistent with differences between the groups in cognition and executive function (i.e., Trail Making Test, Part B and mini-mental state examination) and despite no significant differences with respect to age, education, intelligence, or working memory. None of the survivors and only one control manifested a global positron emission tomography score consistent with an Alzheimer's disease metabolic pattern. CONCLUSION:Breast cancer survivors treated with chemotherapy may manifest long-term changes in brain glucose metabolism indicative of subtle frontal hypometabolism, a finding consistent with results from neuropsychological testing and other imaging modalities.
Authors: Steven A Castellon; Patricia A Ganz; Julienne E Bower; Laura Petersen; Laura Abraham; Gail A Greendale Journal: J Clin Exp Neuropsychol Date: 2004-10 Impact factor: 2.475
Authors: Laura L Boles Ponto; Vincent A Magnotta; David J Moser; Kevin M Duff; Susan K Schultz Journal: Mol Imaging Biol Date: 2006 Nov-Dec Impact factor: 3.488
Authors: Michiel B de Ruiter; Liesbeth Reneman; Willem Boogerd; Dick J Veltman; Frits S A M van Dam; Aart J Nederveen; Epie Boven; Sanne B Schagen Journal: Hum Brain Mapp Date: 2010-07-28 Impact factor: 5.038
Authors: Cay Anderson-Hanley; Marne L Sherman; Raine Riggs; V Bede Agocha; Bruce E Compas Journal: J Int Neuropsychol Soc Date: 2003-11 Impact factor: 2.892
Authors: Jame Abraham; Marc W Haut; Maria T Moran; Shannon Filburn; Susan Lemiuex; Hiroto Kuwabara Journal: Clin Breast Cancer Date: 2008-02 Impact factor: 3.225
Authors: Vincent Koppelmans; Monique M B Breteler; Willem Boogerd; Caroline Seynaeve; Sanne B Schagen Journal: Crit Rev Oncol Hematol Date: 2013-06-13 Impact factor: 6.312
Authors: V Jenkins; V Shilling; G Deutsch; D Bloomfield; R Morris; S Allan; H Bishop; N Hodson; S Mitra; G Sadler; E Shah; R Stein; S Whitehead; J Winstanley Journal: Br J Cancer Date: 2006-03-27 Impact factor: 7.640
Authors: Ana Dias-Carvalho; Mariana Ferreira; Rita Ferreira; Maria de Lourdes Bastos; Susana Isabel Sá; João Paulo Capela; Félix Carvalho; Vera Marisa Costa Journal: Arch Toxicol Date: 2021-11-02 Impact factor: 5.153
Authors: Laura M Zitella; Benjamin A Teplitzky; Paul Yager; Heather M Hudson; Katelynn Brintz; Yuval Duchin; Noam Harel; Jerrold L Vitek; Kenneth B Baker; Matthew D Johnson Journal: Front Comput Neurosci Date: 2015-07-14 Impact factor: 2.380